Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Brazil · Delayed Price · Currency is BRL 1.040
+0.010 (0.97%)
Sep 17, 2026, 5:05 PM GMT-3
BVMF:ONCO3 Income Statement
Financials in millions BRL. Fiscal year is January - December.
Millions BRL. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,990 | 5,739 | 6,227 | 5,489 | 4,088 | 2,702 | |
Revenue Growth | -18.97% | -7.83% | 13.45% | 34.26% | 51.30% | 32.77% |
Cost of Revenue | 3,628 | 3,953 | 4,167 | 3,560 | 2,636 | 1,833 |
Gross Profit | 1,363 | 1,786 | 2,060 | 1,929 | 1,452 | 868.79 |
Selling, General & Admin | 1,279 | 1,361 | 1,397 | 1,172 | 980.82 | 688.05 |
Other Operating Expenses | 2,124 | 1,790 | -20.37 | -13.16 | 0.19 | 3.53 |
Operating Expenses | 3,403 | 3,152 | 1,376 | 1,159 | 981.01 | 691.58 |
Operating Income | -2,040 | -1,365 | 684.02 | 769.67 | 471.1 | 177.22 |
Interest Expense | -622.39 | -648.12 | -728.16 | -563.39 | -490.11 | -154.36 |
Interest & Investment Income | 75.52 | 158.49 | 143.44 | 105.54 | 141.08 | 54.41 |
Earnings From Equity Investments | -19.87 | 0.18 | -7.9 | -11.65 | -0.54 | - |
Currency Exchange Gain (Loss) | 1.74 | 14.68 | -29 | 7.92 | - | - |
Other Non Operating Income (Expenses) | -606.36 | -609.99 | 91.58 | 8.87 | - | -10.98 |
EBT Excluding Unusual Items | -3,212 | -2,450 | 153.98 | 316.95 | 121.54 | 66.29 |
Gain (Loss) on Sale of Investments | -67.11 | -67.11 | - | - | - | - |
Asset Writedown | -625.33 | -625.33 | -796.07 | - | - | - |
Legal Settlements | -16.86 | -20.16 | -14.77 | -14.43 | - | -3.95 |
Pretax Income | -3,921 | -3,163 | -656.86 | 302.52 | 121.54 | 62.34 |
Income Tax Expense | 451.03 | 508.47 | 60.57 | -10.04 | 7.77 | 84.75 |
Earnings From Continuing Operations | -4,372 | -3,671 | -717.43 | 312.56 | 113.77 | -22.42 |
Minority Interest in Earnings | 141.74 | 47.32 | 71.24 | -88.94 | -67.51 | -24.48 |
Net Income | -4,230 | -3,624 | -646.19 | 223.62 | 46.26 | -46.9 |
Net Income to Common | -4,230 | -3,624 | -646.19 | 223.62 | 46.26 | -46.9 |
Net Income Growth | - | - | - | 383.39% | - | - |
Shares Outstanding (Basic) | 869 | 867 | 616 | 524 | 480 | 412 |
Shares Outstanding (Diluted) | 869 | 867 | 616 | 536 | 532 | 412 |
Shares Change | 32.66% | 40.59% | 15.09% | 0.72% | 28.93% | 2.65% |
EPS (Basic) | -4.87 | -4.18 | -1.05 | 0.43 | 0.10 | -0.11 |
EPS (Diluted) | -4.87 | -4.18 | -1.05 | 0.42 | 0.09 | -0.11 |
EPS Growth | - | - | - | 379.95% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 177.67 | -286.75 | -399.1 | -363.26 | -571.82 | -211.23 |
Free Cash Flow Per Share | 0.20 | -0.33 | -0.65 | -0.68 | -1.07 | -0.51 |
Gross Margin | 27.31% | 31.12% | 33.09% | 35.14% | 35.52% | 32.15% |
Operating Margin | -40.88% | -23.79% | 10.98% | 14.02% | 11.52% | 6.56% |
Profit Margin | -84.77% | -63.14% | -10.38% | 4.07% | 1.13% | -1.74% |
Free Cash Flow Margin | 3.56% | -5.00% | -6.41% | -6.62% | -13.99% | -7.82% |
EBITDA | -1,874 | -1,192 | 874.68 | 931.27 | 646.25 | 270.2 |
EBITDA Margin | -37.56% | -20.77% | 14.05% | 16.97% | 15.81% | 10.00% |
D&A For EBITDA | 165.94 | 173.37 | 190.65 | 161.6 | 175.15 | 92.99 |
EBIT | -2,040 | -1,365 | 684.02 | 769.67 | 471.1 | 177.22 |
EBIT Margin | -40.88% | -23.79% | 10.98% | 14.02% | 11.52% | 6.56% |
Effective Tax Rate | - | - | - | - | 6.39% | 135.96% |
Revenue as Reported | 4,990 | 5,739 | 6,227 | 5,489 | 4,088 | 2,702 |